Piyasa Haberleri

En güncel finans ve ekonomi haberlerini, piyasa gelişmelerini, raporları ve analizleri PipVero’da takip edin.

Kaynak: Zacks Investment Research Haber Ajansı
1 ay önce
Hisse Senedi Orta Önem
Intuit (INTU) Advances But Underperforms Market: Key Facts

Intuit (INTU) Advances But Underperforms Market: Key Facts

In the closing of the recent trading day, Intuit (INTU) stood at $323.6, denoting a +1.64% move from the preceding trading day.

İlgili Semboller 1
INTU INTU
Kaynak: Zacks Investment Research
Kaynağı Ziyaret Et
Official Partner ITBFX Start Trading
0 0 0
Devamını Oku
Yorum Yap
Kaynak: Seeking Alpha Haber Ajansı
1 ay önce
Hisse Senedi Orta Önem
SpaceX Q2: A Monster Beat, A Broken Valuation (Strong Sell)

SpaceX Q2: A Monster Beat, A Broken Valuation (Strong Sell)

Space Exploration Technologies Corp. aka SpaceX delivered a spectacular Q2, with $7.81B in revenue and $3.54B in adjusted EBITDA, beating expectations across nearly every major business line. Yet SPCX stock fell about 8% after earnings. Investors were not questioning the growth; they were questioning how much capital SpaceX must spend to produce it. Starlink remains the economic engine of the group, generating $4.29B in revenue and $1.66B in operating profit while AI and Space posted combined operating losses of roughly $1.80B.

İlgili Semboller 1
SPCX SPCX
Kaynak: Seeking Alpha
Kaynağı Ziyaret Et
0 0 0
Devamını Oku
Yorum Yap
Kaynak: Zacks Investment Research Haber Ajansı
1 ay önce
Hisse Senedi Orta Önem
Syndax Pharmaceuticals (SNDX) Reports Q2 Loss, Lags Revenue Estimates

Syndax Pharmaceuticals (SNDX) Reports Q2 Loss, Lags Revenue Estimates

Syndax Pharmaceuticals (SNDX) came out with a quarterly loss of $0.55 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to a loss of $0.83 per share a year ago.

İlgili Semboller 1
SNDX SNDX
Kaynak: Zacks Investment Research
Kaynağı Ziyaret Et
0 0 0
Devamını Oku
Yorum Yap
Kaynak: Zacks Investment Research Haber Ajansı
1 ay önce
Hisse Senedi Orta Önem
Rigel Pharmaceuticals (RIGL) Q2 Earnings Miss Estimates

Rigel Pharmaceuticals (RIGL) Q2 Earnings Miss Estimates

Rigel Pharmaceuticals (RIGL) came out with quarterly earnings of $0.88 per share, missing the Zacks Consensus Estimate of $0.91 per share. This compares to earnings of $3.28 per share a year ago.

İlgili Semboller 1
RIGL RIGL
Kaynak: Zacks Investment Research
Kaynağı Ziyaret Et
0 0 0
Devamını Oku
Yorum Yap
Kaynak: Zacks Investment Research Haber Ajansı
1 ay önce
Hisse Senedi Orta Önem
Personalis (PSNL) Reports Q2 Loss, Tops Revenue Estimates

Personalis (PSNL) Reports Q2 Loss, Tops Revenue Estimates

Personalis (PSNL) came out with a quarterly loss of $0.3 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to a loss of $0.23 per share a year ago.

İlgili Semboller 1
PSNL PSNL
Kaynak: Zacks Investment Research
Kaynağı Ziyaret Et
0 0 0
Devamını Oku
Yorum Yap
Kaynak: Zacks Investment Research Haber Ajansı
1 ay önce
Hisse Senedi Orta Önem
Lumen (LUMN) Reports Q2 Loss, Tops Revenue Estimates

Lumen (LUMN) Reports Q2 Loss, Tops Revenue Estimates

Lumen (LUMN) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to a loss of $0.03 per share a year ago.

İlgili Semboller 1
LUMN LUMN
Kaynak: Zacks Investment Research
Kaynağı Ziyaret Et
0 0 0
Devamını Oku
Yorum Yap
Kaynak: Zacks Investment Research Haber Ajansı
1 ay önce
Hisse Senedi Orta Önem
Allegiant Travel (ALGT) Q2 Earnings Beat Estimates

Allegiant Travel (ALGT) Q2 Earnings Beat Estimates

Allegiant Travel (ALGT) came out with quarterly earnings of $2.19 per share, beating the Zacks Consensus Estimate of $1.27 per share. This compares to earnings of $1.23 per share a year ago.

İlgili Semboller 1
ALGT ALGT
Kaynak: Zacks Investment Research
Kaynağı Ziyaret Et
0 0 0
Devamını Oku
Yorum Yap
Kaynak: Zacks Investment Research Haber Ajansı
1 ay önce
Hisse Senedi Orta Önem
Gilead Sciences (GILD) Reports Q2 Loss, Beats Revenue Estimates

Gilead Sciences (GILD) Reports Q2 Loss, Beats Revenue Estimates

Gilead Sciences (GILD) came out with a quarterly loss of $6.75 per share versus the Zacks Consensus Estimate of a loss of $7.07. This compares to earnings of $2.01 per share a year ago.

İlgili Semboller 1
GILD GILD
Kaynak: Zacks Investment Research
Kaynağı Ziyaret Et
Official Partner ITBFX Start Trading
0 0 0
Devamını Oku
Yorum Yap